Oryzon Genomics S.A. (ORY.MC)
EUR 1.59
(-3.98%)
EUR 1.59
(-3.98%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 13.68 Million EUR | -21.52% |
| 2022 | 17.44 Million EUR | 26.65% |
| 2021 | 13.77 Million EUR | 51.45% |
| 2020 | 9.09 Million EUR | 0.0% |
| 2019 | - EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - USD | -100.0% |
| 2024 Q3 | - EUR | -100.0% |
| 2024 Q2 | 13.38 Million EUR | 0.0% |
| 2023 FY | 13.68 Million EUR | -21.52% |
| 2023 Q1 | 94.07 Thousand EUR | -99.46% |
| 2023 Q2 | 15.07 Million EUR | 15928.93% |
| 2023 Q4 | 13.68 Million EUR | 13.45% |
| 2023 Q3 | 12.06 Million EUR | -19.99% |
| 2022 Q4 | 17.44 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -303.754% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 75.322% |
| Adocia SA | 13.08 Million EUR | -4.579% |
| Aelis Farma SA | 4.03 Million EUR | -238.961% |
| Biophytis S.A. | 8.27 Million EUR | -65.505% |
| Advicenne S.A. | 17.42 Million EUR | 21.451% |
| genOway Société anonyme | 7.23 Million EUR | -89.223% |
| IntegraGen SA | 1.12 Million EUR | -1116.931% |
| Medesis Pharma S.A. | 1.2 Million EUR | -1040.604% |
| Neovacs S.A. | 650 Thousand EUR | -2005.73% |
| NFL Biosciences SA | 62.17 Thousand EUR | -21914.421% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -214.179% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -403.793% |
| Sensorion SA | 2.86 Million EUR | -377.109% |
| Theranexus Société Anonyme | 3.64 Million EUR | -275.711% |
| TME Pharma N.V. | 1.16 Million EUR | -1073.863% |
| Valbiotis SA | 6.87 Million EUR | -99.0% |
| TheraVet SA | 1.15 Million EUR | -1080.07% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | -52.114% |
| argenx SE | 18.1 Million EUR | 24.402% |
| BioSenic S.A. | 28.16 Million EUR | 51.396% |
| Celyad Oncology SA | 902 Thousand EUR | -1417.433% |
| DBV Technologies S.A. | 13.01 Million USD | -5.136% |
| Galapagos NV | 9.59 Million EUR | -42.635% |
| Genfit S.A. | 70.17 Million EUR | 80.496% |
| GeNeuro SA | 7.73 Million EUR | -76.888% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | -158.543% |
| Innate Pharma S.A. | 39.89 Million EUR | 65.69% |
| Inventiva S.A. | 37.4 Million EUR | 63.41% |
| MaaT Pharma SA | 14.07 Million EUR | 2.755% |
| MedinCell S.A. | 58.96 Million EUR | 76.786% |
| Nanobiotix S.A. | 50.56 Million EUR | 72.931% |
| Onward Medical N.V. | 16.87 Million EUR | 18.886% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | 70.116% |
| Oxurion NV | 12.33 Million EUR | -10.972% |
| Pharming Group N.V. | 155.29 Million EUR | 91.186% |
| Poxel S.A. | 46.9 Million EUR | 70.816% |
| GenSight Biologics S.A. | 18.42 Million EUR | 25.726% |
| Transgene SA | 1.25 Million EUR | -988.882% |
| Financière de Tubize SA | 79.2 Million EUR | 82.718% |
| UCB SA | 3.03 Billion EUR | 99.549% |
| Valneva SE | 208.81 Million EUR | 93.445% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -35919.068% |